This FDA Story is an illustrative, anonymized composite created for education. It is not a claim about a named company or a specific FDA enforcement record.
A mid-sized overseas skincare brand had built a successful US business through an importer and several specialist beauty resellers. Its facility registration and product listings were current. Its labels looked polished. The company believed adverse-event reporting was unlikely to matter because it had sold the same formulations in other countries for years without a formal safety complaint. What it did not have was a US intake owner, a case log, or a written rule requiring resellers to escalate health-related messages.
The report reached a reseller first
A consumer contacted a US reseller after using one of the brand's exfoliating products. She described intense burning, blistering, emergency medical treatment, and discoloration that persisted after the initial injury. Those facts could meet MoCRA's serious adverse event definition because they involved medical intervention and potentially a serious burn or significant alteration of appearance. The reseller treated the message as a refund request, issued store credit, and placed the correspondence in its ordinary customer-service queue.
The reseller's monthly summary mentioned 'skin irritation' but omitted the treatment and continuing discoloration. The overseas brand saw no urgency. No one requested photographs, treatment details, the lot code, or permission to follow up. No case was opened, no seriousness decision was documented, and no one calculated the 15-business-day reporting period.
The deadline passed without a filing
By the time a manager reread the original message, more than 15 business days had passed. The company considered filing late but worried that doing so would attract attention. It chose to wait for more information instead. That decision compounded the problem: the brand now had a potentially serious event, no timely MedWatch Form 3500A, no complete adverse-event record, and no controlled follow-up process for the next year.
An inspection surfaced the missing event
Months later, a separate complaint led regulators to examine the facility's complaint and distribution records. The reseller correspondence appeared in a shared folder. Inspectors asked when the Responsible Person received it, how seriousness had been assessed, where the six-year record was kept, and whether a 3500A had been submitted. The company could answer none of those questions consistently. Its label contact also led only to the general reseller inbox that had lost the original report.
One missing case exposed the whole system
The brand now faced more than a late report. Regulators were evaluating a missing adverse-event program, a potentially misbranded contact channel, and whether the underlying reaction suggested a broader product or facility risk. The company was warned that facility-registration suspension could be considered if the statutory serious-health-risk conditions were established. An incoming shipment was held while the importer worked through the labeling and safety questions, and the brand voluntarily paused distribution and prepared for a possible recall while it investigated the lot.
Sales stopped while the company hired advisers, reconstructed the original complaint, created procedures, trained resellers, revised label contact information, and prepared late and follow-up submissions. None of that work was unusually complicated. It was simply being done at the worst possible time — during an inspection and shipment hold, when every day created commercial loss.
The lesson
The failure was not that the brand could have prevented every reaction. It was that no one owned what happened after a report arrived. A compliant program needs one monitored channel, immediate reseller escalation, a complete case record, a documented seriousness assessment, a 15-business-day deadline owner, one-year follow-up, and retained filing evidence. FDABridge's FDA Adverse Event Management service provides that function before the first report tests the system.
Need a compliant cosmetic adverse-event program?
We manage intake, seriousness assessment, FDA filings, follow-up, and audit-ready records under MoCRA.